Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
Condition: Leiomyosarcoma Intervention: Drug: Dinutuximab Beta, Zoledronic acid, Interleukin-2 Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; EUSA Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2021 Category: Research Source Type: clinical trials